Article Text

Download PDFPDF
Anti-IL-1 agents: a paradigm shift in medical therapy for recurrent pericarditis?
  1. Massimo Imazio1,2
  1. 1 University Cardiology, Cardiovascular and Thoracic Department, AOU Città della Salute e della Scienza di Torino, Torino, Italy
  2. 2 Department of Public Health and Pediatrics, University of Torino, Torino, Italy
  1. Correspondence to Professor Massimo Imazio, University Cardiology, Cardiovascular and Thoracic Department, AOU Città della Salute e della Scienza di Torino, 10126 Torino, Italy; massimo_imazio{at}yahoo.it

Statistics from Altmetric.com

Recurrent pericarditis is one of the most troublesome complications of pericarditis, affecting 15%–30% of patients with a first episode of pericarditis1 2 and often severely affecting the quality of life of patients. Colchicine has been demonstrated to be a safe and efficacious treatment to halve the recurrence rate either in acute or recurrent episodes at 18 months also after drug withdrawal after 3–6 months of therapy,1 2 and it is a mainstay of medical therapy in association with non-steroidal anti-inflammatory drugs and/or corticosteroids at low to moderate doses3 according to 2015 European Society of Cardiology guidelines with a class IA indication.4 However, 5%–10% of patients with recurrent pericarditis cannot achieve disease control with a combination of these therapies and may become corticosteroid-dependent and colchicine resistant, often with significant side effects related to the chronic use of corticosteroids.5 For these patients, new therapies are needed beyond traditional approaches, and anti-interleukin (IL)-1 agents, such as rilonacept, have been recently proposed as new drugs in this clinical setting.

The current paper6 reports an open-label, single-arm, phase II study evaluating the efficacy and safety of rilonacept in 25 adult patients (mean age 43 years, 60% women) with idiopathic or postpericardiotomy recurrent pericarditis with a least two recurrences and active disease or corticosteroid dependence evaluated at nine sites in the USA from January 2018 to May 2019. Rilonacept is an IL-1 trap active on either IL-1-α and IL-1-β, and was given subcutaneously with a loading dose of 320 mg for the first day followed by a maintenance dose of 160 mg weekly for 6 weeks and extended to an optional time of 18 weeks (total treatment time of 6 months).

A single dose of rilonacept was able to reduce either pericarditis pain or C reactive protein (CRP) with a median normalisation …

View Full Text

Footnotes

  • Contributors MI confirmed that the paper is original and approved for submission. MI is the sole author of this editorial.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests MI has been advisory board member for Sobi and Kiniksa.

  • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

  • Patient consent for publication Not required.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles